appropriation; midomafetamine; research

Arizona's SB 1460 allocates $10 million from the state general fund for fiscal year 2025-2026 to the Department of Health Services to fund grants for research on midomafetamine as a treatment for post-traumatic stress disorder (PTSD). The grants are limited to entities that have completed at least one late-stage clinical trial for midomafetamine and are currently in U.S. Food and Drug Administration review for PTSD treatment. This funding is exempt from standard appropriation lapsing rules under Arizona law. The bill directly affects qualified research organizations conducting specific clinical trials, not the general public.